Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Assets Average (2016 - 2025)

Historic Assets Average for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to $90.2 million.

  • Lineage Cell Therapeutics' Assets Average fell 950.77% to $90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.2 million, marking a year-over-year decrease of 950.77%. This contributed to the annual value of $107.1 million for FY2024, which is 464.92% down from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Assets Average of $90.2 million as of Q3 2025, which was down 950.77% from $101.3 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Assets Average high stood at $159.5 million for Q1 2022, and its period low was $90.2 million during Q3 2025.
  • Its 5-year average for Assets Average is $118.9 million, with a median of $112.5 million in 2025.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Assets Average skyrocketed by 4488.18% in 2021 and then crashed by 2576.15% in 2023.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Assets Average stood at $152.9 million in 2021, then decreased by 16.66% to $127.4 million in 2022, then decreased by 18.7% to $103.6 million in 2023, then rose by 1.27% to $104.9 million in 2024, then dropped by 14.0% to $90.2 million in 2025.
  • Its Assets Average stands at $90.2 million for Q3 2025, versus $101.3 million for Q2 2025 and $112.5 million for Q1 2025.